This trial is conducted in Europe. Tha aim of this trial is to investigate the effect of oral semaglutide on the pharmacokinetics of furosemide and rosuvastatin in healthy subjects.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
41
Oral administration A total of three single doses.
Oral administration. A total of three single doses.
Oral administration. A total of five single doses.
Novo Nordisk Investigational Site
Harrow, United Kingdom
Area under the furosemide plasma concentration-time curve
Based on sampling between 0 and 12 hours
Time frame: day 1, day 7, day 54
Area under the rosuvastatin plasma concentration-time curve
Based on sampling between 0 and 96 hours
Time frame: day 2, day 8, day 55
Maximum observed furosemide plasma concentration
Time frame: day 1, day 7, day 54
Maximum observed rosuvastatin plasma concentration
Time frame: day 2, day 8, day 55
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Oral administration. Once daily.